U.S., Dec. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07282015) titled 'Real-world Secukinumab Outcomes in Canadian HS Patients' on Dec. 02.
Brief Summary: The HS-RISE study aims to assess real-world HS treatment outcomes and patterns, safety of secukinumab, and to describe the baseline characteristics of patients diagnosed with moderate-to- severe HS who are prescribed secukinumab in Canadian routine clinical practice.
Study Start Date: Dec. 15
Study Type: OBSERVATIONAL
Condition:
Hidradenitis Suppurativa
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Novartis Pharmaceuticals
Published by HT Digital Content Services with permission from Health Daily Digest....